BioLineRx (NASDAQ:BLRX – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Risk and Volatility
BioLineRx has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioLineRx and Biomerica”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLineRx | $1.18 million | 10.44 | -$1.17 million | ($1.92) | -1.47 |
| Biomerica | $5.31 million | 0.92 | -$4.97 million | ($0.89) | -1.78 |
BioLineRx has higher earnings, but lower revenue than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 18.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares BioLineRx and Biomerica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -563.70% | -37.73% | -19.42% |
| Biomerica | -96.49% | -98.14% | -70.42% |
Analyst Recommendations
This is a summary of current ratings and target prices for BioLineRx and Biomerica, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
Biomerica has a consensus target price of $9.00, suggesting a potential upside of 467.82%. Given Biomerica’s higher probable upside, analysts clearly believe Biomerica is more favorable than BioLineRx.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
